- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AHA Backs Decision to Keep Status Quo on EMTALA
The American Hospital Association announced its support for the CMS' decision to leave the current Emergency Medical Treatment & Labor Act regulations unaltered.
“The current policies are the appropriate interpretation of the law and are achieving what Congress intended,” the AHA comments read (PDF). “They do not need to be revisited. If anything, a move by CMS to expand the scope of EMTALA is out-of-step with President Obama's call for improving regulations by minimizing burden and unnecessary regulation.” Read the full story: http://hcp.lv/GY7w4B
Source: ModernHealthcare
The AHA submitted comments Monday to the CMS backing the choice. The government made its announcement earlier this year that it would maintain status quo.
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More
